搜索
 > 【Angiopoietin-2】重组蛋白信息

Angiopoietin-2信息

英文名称:Angiopoietin-2
中文名称:血管生成素-2
靶点别称:Angiopoietin-2,ANGPT2,ANG-2
上市药物数量:0
临床药物数量:11
最高研发阶段:临床三期

Angiopoietin-2产品列表

 
评论(0)
 

Angiopoietin-2 Molecule Synonym Name

ANGPT2,AGPT2,ANG2,Angiopoietin-2

Angiopoietin-2 分子背景

Angiopoietin-2 is also known as ANGPT2, AGPT2, ANG2, and is a secreted glycoprotein that plays a complex role in angiogenesis and inflammation. Ang2 is widely expressed during development, but it is restricted postnatally to highly angiogenic tissues such as the placenta, ovaries, and uterus. It is particularly abundant in vascular endothelial cells (EC) where it is stored in intracellular Weibel Palade bodies. Both Ang2 and the related Angiopoietin1 (Ang1) are ligands for the receptor tyrosine kinase Tie 2. Ang2 functions as a proangiogenic factor, although it can also induce EC death and vessel regression. Upon its release from quiescent EC, it regulates vascular remodeling by promoting EC survival, proliferation, and migration and destabilizing the interaction between EC and perivascular cells. Ang2 is required for postnatal vascular remodeling, and it cooperates with Ang1 during lymphatic vessel development. It mediates the upregulation of ICAM1 and VCAM1 on EC, which facilitates the adhesion of leukocytes during inflammation. Ang2 competitively inhibit Ang1-induced endothelial cell responses mediated by Tie2, and reduces vascular integrity. But the role of Ang2 is controversial since the opposite outcomes has been reported in other studies. Over-expression of Ang2 disrupts the vascular remodeling, induce endothelial cell apoptosis, and may play an important regulating role in tumor angiogenesis. Ang2 also promotes the neuronal differentiation and migration of subventricular zone progenitor cells.

Angiopoietin-2 参考文献

Angiopoietin-2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Faricimab RG-7716; RO-6867461 临床三期 罗氏 糖尿病性黄斑水肿, 湿性年龄相关性黄斑变性 详情
AMG-780 AMG-780 临床一期 安进 实体瘤 详情
PF-5057459 CovX-241; CVX-241; PF-05057459 临床一期 辉瑞 实体瘤 详情
MEDI-3617 MEDI-3617; ANG-2-mAb; Anti-ANG-2-mAb,MEDI3617 临床一期 MedImmune 实体瘤, 黑色素瘤 详情
Trebananib AMG-386; 20060439 ,AMG386 临床三期 安进, 武田 输卵管癌, 腹膜癌, 卵巢癌 详情
PF-4856884 CovX 060; CVX-060; PF-04856884 临床二期 CovX Pharmaceuticals, 辉瑞 实体瘤, 肾癌 详情
Vanucizumab RG-7221; RO-5520985; B800Z06O8K (UNII code),RG7221; RO5520985 临床二期 罗氏 实体瘤, 结肠直肠癌 详情
Nesvacumab REGN-910; SAR-307746 临床一期 再生元制药, 赛诺菲 实体瘤 详情
LY-3127804 LY-3127804,LY3127804 临床一期 礼来 胃癌, 实体瘤, 肝细胞癌 详情
BI-836880 BI-836880 临床一期 Ablynx, 勃林格殷格翰 非小细胞肺癌, 实体瘤, 湿性年龄相关性黄斑变性 详情
Aflibercept/Nesvacumab REGN 910-3 临床二期 再生元制药, 拜耳 糖尿病性黄斑水肿, 湿性年龄相关性黄斑变性 详情

消息提示

请输入您的联系方式,再点击提交!

确定